Arterys Cardio DL vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Arterys Cardio DL

by Arterys (now part of Tempus)

iPredict Eye Screening

by iHealthScreen

AI Verdict

Tool A is designed for detailed diagnostic analysis of cardiac MRIs, providing automated segmentations to aid cardiologists and radiologists. Tool B, conversely, focuses on AI-powered screening for retinal diseases and predicting systemic risks like stroke and heart attack from eye scans. While both leverage AI in cardiology-related areas, their distinct methodologies (MRI analysis vs. retinal screening) and primary clinical applications make them suitable for different diagnostic and screening workflows.

Choose Arterys Cardio DL if…

Choose Arterys Cardio DL if your cardiology department or radiology practice requires highly accurate, automated ventricle segmentations and advanced quantitative analysis for cardiac MRI studies. This cloud-based AI solution is ideal for significantly reducing interpretation time and enhancing diagnostic precision for complex cardiac conditions, including detailed blood flow visualization and quantification.

View Arterys Cardio DL →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if you are a primary care provider, ophthalmologist, or telemedicine service seeking an efficient, AI-powered tool for early detection of multiple retinal diseases like AMD, DR, and Glaucoma. This platform is particularly well-suited for integrating systemic disease risk prediction (stroke, heart attack) into routine patient screenings, offering quick, non-invasive results in diverse clinical settings.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Arterys Cardio DL	iPredict Eye Screening
Pricing	Unknown	Contact for pricing
Deployment	Cloud-based (SaaS), integrates with existing PACS or EHR, web-based zero-footprint viewer (Mac, PC, tablet, phone). [4, 7, 9, 13, 27]	Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

iPredict Eye Screening

Both tools emphasize ease of use and speed. However, Tool B explicitly highlights an 'easy to operate' system with an 'advanced touchscreen interface' and 'fast results' (test in <5 minutes, report in <60 seconds), directly addressing a streamlined user experience for its screening task. Tool A focuses on reducing complex MRI interpretation time, which is also a usability benefit, but Tool B's description suggests a more intuitive, dedicated interface for its primary users.

Clinical Value

iPredict Eye Screening

Both are FDA-cleared and offer significant clinical value in their respective specialties. Tool B offers a broader clinical scope, screening for multiple ocular diseases (Diabetic Retinopathy, AMD, Glaucoma) and providing risk prediction for systemic conditions like stroke and heart attack. This multi-disease screening and predictive capability for systemic conditions offers a wider range of clinical utility compared to Tool A's focus on enhancing cardiac MRI diagnostics.

Pricing & Value

iPredict Eye Screening

Tool B provides greater transparency regarding its pricing model, stating it's a 'Per patient screening on a Software as a Service (SaaS) model, estimated $10-$20 per patient (20%-40% of Medicare/commercial payor reimbursement)'. Tool A only states 'contact for pricing'. This clear pricing structure for Tool B offers better value clarity for potential buyers.

Enterprise Readiness

Arterys Cardio DL

Both are cloud-based, FDA-cleared, and HIPAA compliant. However, Tool A explicitly states 'has_baa: 1' and 'Vendor-agnostic compatibility', which are crucial for enterprise-level compliance and integration. While Tool B mentions EHR integration, the explicit BAA and vendor-agnosticism for Tool A provide a stronger foundation for formal enterprise readiness.

Innovation

iPredict Eye Screening

Both demonstrate significant innovation in their fields. Tool B demonstrates broader innovation by applying AI to screen for multiple ocular diseases and extending its capabilities to predict systemic diseases like stroke and heart attack. Its integration with telemedicine and an online health risk prediction system showcases a more diverse and forward-thinking application of AI in healthcare beyond a single diagnostic area.

Support & Docs

Tie

Neither the provided structured facts nor general web searches offer specific comparative details on the quality, depth, or responsiveness of support and documentation for either tool. Both companies provide standard contact methods for support, but without further information, a distinction cannot be made.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Arterys Cardio DL	iPredict Eye Screening
Product Name	Arterys Cardio DL	iPredict Eye Screening
Company	ARTERYS	iHealthScreen
Description	FDA-cleared, cloud-based AI software that provides automated, editable ventricle segmentations for cardiac MRI analysis, drastically reducing interpretation time and enhancing diagnostic accuracy.	FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services.
Key Features	Automated ventricle segmentations for cardiac MRI; Deep learning algorithms for image analysis; Cloud-based platform for accessibility and performance; Vendor-agnostic compatibility; Rapid analysis (seconds vs. 30-60 minutes); Editable automated contours; 4D Flow post-processing for blood flow visualization and quantification; Quantitative Delayed Enhancement analysis	AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; Electronic Health Record (EHR) Solutions; AI-Based Telemedicine Service; Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector; Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients; Fast results: test completed in less than 5 minutes, report in under 60 seconds; High accuracy: approximately 95% on average (AMD sensitivity 86.86%, specificity 94.13%); Easy to operate, non-invasive, with an advanced touchscreen interface
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Neurology AI, Ophthalmology AI
Specialties	Cardiology, Radiology	Family Medicine, Internal Medicine, Ophthalmology

Videos

Demos, reviews, and walkthroughs featuring Arterys Cardio DL and iPredict Eye Screening.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do Arterys Cardio DL and iPredict Eye Screening integrate into existing clinical workflows, and what specific time savings or efficiency gains can a physician expect?

Arterys Cardio DL drastically reduces cardiac MRI interpretation time, providing automated, editable ventricle segmentations in seconds compared to 30-60 minutes for manual analysis, enhancing diagnostic accuracy. iPredict Eye Screening offers rapid, non-invasive screening for retinal diseases, completing tests in less than 5 minutes with reports generated in under 60 seconds, streamlining early detection in primary care and other settings.

What is the extent of EHR integration offered by each tool, and what specific data exchange capabilities are supported?

iPredict Eye Screening explicitly states integration with EHR and telemedicine services, offering Electronic Health Record (EHR) Solutions to streamline patient information. Arterys Cardio DL integrates with existing PACS or EHR driven workflows, allowing AI clinical applications to become a natural extension of current practices.

Can you detail the specific accuracy metrics for each tool and explain their direct clinical implications for patient diagnosis and management?

Arterys Cardio DL provides automated ventricle segmentations for cardiac MRI that are as accurate as those performed manually by experienced physicians, enhancing diagnostic accuracy for heart problems. iPredict Eye Screening demonstrates high accuracy, with approximately 95% on average for its screenings, including an AMD sensitivity of 86.86% and specificity of 94.13%, which directly supports early detection and timely referral for retinal and systemic diseases.

What is the expected learning curve for clinical staff to become proficient with each tool, considering their design and operational requirements?

Arterys Cardio DL, with its automated and editable ventricle segmentations, aims to simplify complex cardiac MRI analysis, suggesting a reduced learning curve by eliminating tedious manual tasks. iPredict Eye Screening is designed to be easy to operate and non-invasive, featuring an advanced touchscreen interface, which indicates a low learning curve for clinical staff.

Beyond their primary functions, what unique advanced clinical features do these tools offer to further enhance diagnostic capabilities or patient care?

Arterys Cardio DL offers advanced features like 4D Flow post-processing for blood flow visualization and quantification, and Quantitative Delayed Enhancement analysis to provide more comprehensive cardiac insights. iPredict Eye Screening extends beyond eye disease screening to include an online health risk prediction system for systemic diseases such as stroke and heart attack, adding a preventative health dimension.